Peptide Therapy Safety: What to Know Before Starting Treatment

A physician’s perspective on the benefits, potential side effects, compounded formulations, criteria for patient selection, and appropriate monitoring protocols

By Stephen Petteruti, DO

Board-Certified Family Physician  |  Founder, Intellectual Medicine  |  Last reviewed August 2026

Peptide therapy has expanded beyond specialty medical practices and is now frequently discussed in podcasts, social media, wellness clinics, and online marketplaces. Patients often present to my office with screenshots, product names, and assertive claims regarding healing, fat loss, muscle growth, recovery, sexual health, or longevity. Their initial questions are typically appropriate: Are peptides safe? Are peptides steroids? Is peptide therapy FDA approved?

My response is never a simple affirmation or denial. The term peptide refers to a broad scientific category, not a single treatment. For example, insulin is a peptide. Several FDA-approved medications for diabetes, weight management, fertility, and endocrine disorders are peptides. In contrast, other products marketed as research peptides often lack substantial human evidence and have not undergone FDA review for safety, efficacy, or manufacturing quality.

In my clinical practice, I do not assess peptide therapy based on popularity or marketing claims. Instead, I evaluate the specific molecule, the intended therapeutic goal, the quality of supporting evidence, the patient’s medical history, the source of the medication, and the proposed monitoring strategy. These factors collectively determine whether a treatment warrants consideration.

Are Peptides Steroids?

No. Peptides and anabolic steroids are different substances. Peptides consist of amino acids. Steroid hormones come from cholesterol, and anabolic steroids are structurally related to testosterone.

Confusion often arises because certain peptides influence hormonal pathways. Depending on the specific medication, a peptide may affect appetite, blood glucose, metabolism, inflammation, pituitary hormones, growth hormone, or insulin-like growth factor 1 (IGF-1). Although a growth hormone-releasing peptide is not classified as an anabolic steroid, it can still produce significant hormonal and metabolic effects.

The primary distinction between peptide therapy and anabolic steroids lies in their chemical structures and mechanisms of action. However, both require a valid clinical indication, precise dosing, informed consent, and ongoing follow-up. The designation ‘not a steroid’ should never be interpreted as ‘free of risk.’

Are Peptides Safe?

Certain peptide medications are supported by robust clinical evidence and have established safety profiles for specific indications. Others possess limited human research, uncertain long-term effects, or additional quality concerns when compounded. Safety is determined by the specific treatment, not by the general category.

When evaluating patient selection for peptide therapy, I begin with five key questions: What condition are we addressing? What human evidence supports this application? Is there an FDA-approved alternative? What aspects of the patient’s history alter the risk profile? How will benefit be measured and harm identified?

I also consider whether the anticipated benefit justifies the associated costs, need for injections, uncertainties, and required follow-up. Treatment should not be chosen solely due to online trends, claims of being natural, or promotion as regenerative. Establishing a clear therapeutic goal is essential.

Is Peptide Therapy FDA Approved?

There is no universal answer, as peptide therapy does not refer to a single medication. Many individual peptide drugs have received FDA approval for specific medical conditions. Such approval applies to a particular product, formulation, dosage, route of administration, and intended use. It does not extend to all peptides, off-label uses, or compounded formulations.

Compounded medications do not receive FDA approval. The FDA does not evaluate each compounded product for safety, efficacy, or quality prior to patient use. Compounding remains appropriate when an approved product does not address a patient’s specific medical requirements. The rationale for compounding should be explicit, and the associated uncertainties must be communicated.

I also emphasize to patients that a compounded formulation is not equivalent to an FDA-approved generic; these terms are not interchangeable. When an FDA-approved treatment is available and appropriate, its regulatory review and manufacturing controls are important considerations in the decision-making process.

What Does Category 1 Mean?

The term Category 1 compounded peptide can lead to misplaced confidence. Under the FDA’s Section 503A framework, Category 1 refers to nominated bulk drug substances for which sufficient information exists to allow FDA evaluation. These substances are still under review.

Category 1 status does not indicate FDA approval, proven efficacy, established safety, FDA endorsement, or universal suitability. It is strictly a regulatory classification rather than a clinical recommendation. The FDA also maintains categories for substances with significant safety concerns or insufficient supporting information.

Regulatory status may change as new evidence emerges and the agency reviews progress. Before I consider prescribing a compounded peptide, I seek up-to-date information regarding the substance, the compounding pharmacy, the formulation, and the intended route of administration.

Common Peptide Therapy Side Effects

The side effects of peptide therapy vary depending on the specific molecule, dosage, route of administration, and individual patient factors. Common adverse reactions include pain, redness, swelling, bruising, or itching at the injection site. Additional reported effects include nausea, gastrointestinal discomfort, appetite changes, headache, flushing, fatigue, dizziness, and fluid retention.

Certain peptides can influence blood pressure, glucose regulation, hormone concentrations, growth factors, or pituitary function. Allergic reactions, immune responses, and interactions with prescription medications, hormones, or supplements also warrant careful consideration. It is inappropriate to generalize the side-effect profile of one peptide to all others.

When discussing risks with patients, I distinguish between established knowledge and areas of uncertainty. Limited evidence does not confirm a treatment’s safety or its lack thereof. This distinction is essential to the informed consent process.

Peptide Injection Risks

Peptide injections present risks related to preparation, sterility, storage, measurement, and administration. Complications may occur if a product is contaminated, improperly manufactured, stored outside the recommended temperature range, incorrectly reconstituted, or administered with suboptimal technique.

Dosing errors represent an additional concern. Confusion may arise among milligrams, micrograms, units, vial concentrations, and syringe markings. Patients should receive both written instructions and direct education regarding preparation, measurement, storage, and administration of the medication.

Compounded injectable peptides present additional concerns regarding identity, potency, purity, consistency, aggregation, and the potential for unintended immune responses. The FDA has specifically addressed immunogenicity risks associated with impurities and peptide aggregates, especially in injectable formulations. Even a potentially appropriate treatment becomes unsafe if the product or instructions lack reliability.

Who Is a Good Candidate for Peptide Therapy?

Appropriate patient selection for peptide therapy starts with a clear diagnosis or defined health concern and a measurable objective. The process should not begin by selecting from a list of products. Before prescribing, I determine the expected outcome, the method of measurement, which established treatments have been considered, and the criteria for adjusting or discontinuing therapy.

The clinical evaluation should encompass symptoms, diagnoses, allergies, current medications, supplements, hormone therapies, prior treatment responses, and individual goals. Particular attention should be given to cancer history, pregnancy, metabolic diseases, endocrine disorders, cardiovascular risk, renal or hepatic impairment, and sleep-disordered breathing when these factors are relevant to the peptide’s mechanism of action.

Certain peptides can affect glucose levels, blood pressure, fertility, pituitary hormones, growth hormone, or IGF-1. A product that is appropriate for one individual may be unsuitable for another. Therefore, an online questionnaire or a brief sales call cannot substitute for a comprehensive medical evaluation.

Monitoring Peptide Therapy Patients

No standardized laboratory panel exists for all peptides. Monitoring protocols should be tailored to the specific treatment, anticipated effects, and the patient’s medical history. Prior to initiating therapy, I establish baseline values, review current medications and medical conditions, and define the clinical outcome to be monitored.

Depending on the specific peptide, laboratory assessments may include glucose, cholesterol, renal and hepatic function, thyroid function, hormone concentrations, or IGF-1 levels. Follow-up should evaluate side effects, injection site reactions, dosing accuracy, medication adjustments, and the presence of measurable therapeutic benefit.

Treatment should be modified or discontinued if significant side effects occur, laboratory findings raise concerns, product quality is questionable, or the patient derives no meaningful benefit. Continuing therapy without a defined clinical endpoint does not reflect prudent medical practice.

Questions to Ask About a Compounding Pharmacy

Patients should be informed about which pharmacy prepares their medication and the rationale for the clinician’s selection. It is important to inquire whether the pharmacy adheres to federal and state compounding regulations and whether the product undergoes testing for identity, strength, purity, stability, and sterility.

Patients should also receive explicit information regarding concentration, dosage, beyond-use date, refrigeration requirements, shipping conditions, and procedures following a temperature excursion. It is advisable to ask how the pharmacy manages adverse reactions, product complaints, recalls, damaged shipments, and product replacements.

While these questions cannot eliminate all risks, they assist both patient and clinician in determining whether the source, product, and instructions meet an acceptable standard of care.

My Approach to Clinical Decision-Making in Peptide Therapy

I approach peptide therapy with the same rigor applied to any prescription. I communicate the expected therapeutic effects, the strength and limitations of the supporting evidence, FDA approval status or compounding details, known and unknown risks, and available alternative treatments.

Prior to initiating therapy, the patient and I establish a shared definition of treatment success. Outcomes may include symptom improvement, laboratory values, body composition, metabolic health, sexual function, recovery, or other measurable parameters. The treatment plan should specify reassessment intervals, criteria for dose adjustment, and indications for discontinuation.

Peptides are occasionally marketed as shortcuts to health. I do not consider them as such. They do not substitute for nutrition, resistance training, adequate sleep, metabolic health, or addressing underlying diagnoses. When I incorporate peptides, they serve as one component within a comprehensive treatment strategy.

Why Your Clinician’s Training Matters

Peptide therapy encompasses more than product selection and dose calculation. Each treatment possesses distinct mechanisms of action, supporting evidence, risk profiles, storage requirements, and monitoring protocols. Clinicians should possess a thorough understanding of the peptide’s effects and the limitations of current research.

Physician training in peptide therapy should address patient selection, dosing, regulatory considerations, product quality, injection technique, side-effect management, and laboratory monitoring. Training should also equip clinicians to evaluate compounding pharmacies and to clearly explain reconstitution, refrigeration, measurement, and administration procedures.

A prescription alone does not guarantee treatment appropriateness. The quality of the clinical evaluation, product, instructions, and follow-up are all critical. If your clinician cannot articulate the treatment goal, supporting evidence, product source, associated risks, and monitoring plan, further inquiry is warranted before initiating therapy.

The Practical Answer for Patients

Peptides differ fundamentally from steroids. Certain peptide medications are supported by robust evidence and established safety profiles, while others lack extensive human research or present additional concerns due to compounding or injectable administration. The essential question is not whether all peptides are safe, but whether a specific peptide is appropriate for you, sourced reliably, and accompanied by a clear therapeutic goal and monitoring strategy.

Interest in peptide therapy is understandable; however, casual prescribing is inappropriate. Patients deserve explanations that distinguish evidence from marketing and provide clear criteria for evaluating treatment effectiveness.

Learn More About Peptide Therapy

Patients considering peptide therapy at Intellectual Medicine may schedule a consultation to review their health history, current medications, treatment goals, laboratory findings, and available options. The purpose of the consultation is to determine the suitability of a specific therapy for the patient, rather than to promote a predetermined product.

Healthcare providers interested in structured education may consider Intellectual Medicine University’s courses, including Regenerative Peptide Therapy: Clinical Applications and Protocols and Growth Hormone-Releasing Peptides: Clinical Applications and Protocols. These trainings emphasize evidence-based practice, patient selection, dosing, safety, compounded products, and monitoring.

About Dr. Stephen Petteruti

Dr. Stephen Petteruti, DO, is a board-certified family physician and founder of Intellectual Medicine. His clinical practice emphasizes individualized preventive, metabolic, hormonal, and longevity medicine. He educates healthcare professionals on evaluating emerging therapies using evidence, patient selection, product quality, monitoring, and clear clinical decision-making. Dr. Petteruti is the best-selling author of Fight Cancer Like a Man and host of the Intellectual Medicine Podcast.

Medical and Editorial Standards

This article was authored from Dr. Petteruti’s clinical perspective and reviewed in accordance with current FDA information on human drug compounding and bulk drug substances. Regulatory classifications are subject to change. The source list below reflects information available at the time of review in August 2026.

References

1. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated September 16, 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
2. U.S. Food and Drug Administration. Consumer and Health Care Professional Information. Updated June 9, 2026. https://www.fda.gov/drugs/human-drug-compounding/consumer-and-health-care-professional-information
3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Updated May 14, 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. Accessed August 5, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
5. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-128. https://pubmed.ncbi.nlm.nih.gov/25450771/